US Patent Office grants patent for Olanzapine-based nausea/vomiting treatment (Starton Therapeutics' STAR-OLZ).
US Patent and Trademark Office has granted US Patent #11,975,112 for "Treatment of Vomiting and Nausea with Minimum Dose of Olanzapine." Olanzapine, used for schizophrenia and bipolar disorder, is also commonly used off-label for anti-nausea. Starton Therapeutics' STAR-OLZ, set to enter a Phase 2 clinical trial, aims to be the first product with total control over CINV (chemotherapy-induced nausea and vomiting).
May 20, 2024
3 Articles